Literature DB >> 2150643

Maternal and fetal cardiovascular changes after intravenous injections of isradipine to pregnant women.

I Ingemarsson1, D Wide-Swensson, K E Andersson, S Arulkumaran.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150643     DOI: 10.2165/00003495-199000402-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  4 in total

1.  Effects of isradipine, a new calcium antagonist, on postpartum uterine activity.

Authors:  I Ingemarsson; S Arulkumaran; D Wide-Swensson; A Forman; K E Andersson; S S Ratnam
Journal:  Acta Obstet Gynecol Scand       Date:  1989       Impact factor: 3.636

2.  Effects of isradipine, a new calcium antagonist, on maternal cardiovascular system and uterine activity in labour.

Authors:  D Wide-Swensson; I Ingemarsson; S Arulkumaran; K E Andersson
Journal:  Br J Obstet Gynaecol       Date:  1990-10

3.  Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep.

Authors:  B Harake; R D Gilbert; S Ashwal; G G Power
Journal:  Am J Obstet Gynecol       Date:  1987-10       Impact factor: 8.661

4.  Effects of calcium entry blocker (nicardipine) tocolysis in rhesus macaques: fetal plasma concentrations and cardiorespiratory changes.

Authors:  C A Ducsay; J S Thompson; A T Wu; M J Novy
Journal:  Am J Obstet Gynecol       Date:  1987-12       Impact factor: 8.661

  4 in total
  3 in total

Review 1.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 2.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

Review 3.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.